Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
9.11
+0.02 (0.22%)
At close: Mar 28, 2025, 4:00 PM
9.00
-0.11 (-1.21%)
After-hours: Mar 28, 2025, 7:54 PM EDT

Gyre Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022
Period Ending
Dec '24 Dec '23 Dec '22
Revenue
105.76113.45102.29
Revenue Growth (YoY)
-6.78%10.91%-
Cost of Revenue
3.884.644.79
Gross Profit
101.87108.8197.5
Selling, General & Admin
73.6275.8271.61
Research & Development
12.0213.7816.69
Operating Expenses
85.6489.688.29
Operating Income
16.2319.219.2
Interest & Investment Income
1.551.040.73
Earnings From Equity Investments
-0.04-1.31-0.25
Currency Exchange Gain (Loss)
-1.5-1.5-4.9
Other Non Operating Income (Expenses)
6.95-8.973.73
EBT Excluding Unusual Items
23.188.488.51
Gain (Loss) on Sale of Assets
-0.07-3.34-
Other Unusual Items
0.110.9
Pretax Income
23.22-76.979.41
Income Tax Expense
5.328.525.1
Earnings From Continuing Operations
17.9-85.484.31
Minority Interest in Earnings
-5.81-7.45-2.01
Net Income
12.09-92.932.3
Net Income to Common
12.09-92.932.3
Shares Outstanding (Basic)
856664
Shares Outstanding (Diluted)
1026676
Shares Change (YoY)
55.39%-13.02%-
EPS (Basic)
0.14-1.410.04
EPS (Diluted)
0.05-1.410.03
Free Cash Flow
-5.9617.385.69
Free Cash Flow Per Share
-0.060.260.07
Gross Margin
96.33%95.91%95.31%
Operating Margin
15.35%16.93%9.00%
Profit Margin
11.43%-81.92%2.25%
Free Cash Flow Margin
-5.63%15.32%5.56%
EBITDA
17.8220.3310.33
EBITDA Margin
16.85%17.92%10.10%
D&A For EBITDA
1.591.111.13
EBIT
16.2319.219.2
EBIT Margin
15.35%16.93%9.00%
Effective Tax Rate
22.91%-54.16%
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q